去氨加压素对颅内出血患者高渗盐水疗效的影响
本研究为单中心回顾性观察性病历审查,纳入颅内出血并接受高渗盐水输注的患者,去氨加压素组25例与高渗盐水单用组1:1匹配25例。主要终点为达到钠目标145-155 mEq/L,两组相似(80% vs. 88%)。次要终点无差异。亚组分析中,高渗盐水单用组在48小时内达到预设钠目标150-155 mEq/L的比例更高(82% vs. 60%,p=0.042)。结论认为去氨加压素不负面影响达到145-155 mEq/L钠目标的能力,但在更高钠目标下可能降低高渗盐水有效性。
要点
- 颅内出血患者使用去氨加压素后,达到钠目标145-155 mEq/L的比例与高渗盐水单用组相似(80% vs. 88%)。
- 在需要更高钠目标(150-155 mEq/L)的患者中,去氨加压素组48小时内达标率更低(60% vs. 82%,p=0.042)。
- 去氨加压素组与高渗盐水单用组在ICU住院时间、住院时间、钠变化、达标时间、血栓事件、死亡率及复合神经恶化终点上均无差异。
- 本研究为单中心回顾性观察性研究,样本量小(每组25例),结果需前瞻性验证。
- 对于接受高渗盐水治疗且需较高钠目标的颅内出血患者,使用去氨加压素时应关注钠达标情况。
适用人群与场景
- 诊断为颅内出血并接受高渗盐水输注的患者;去氨加压素组需有去氨加压素使用记录。
- 单中心回顾性研究,纳入的患者来自该中心;排除标准原文未提及。
诊断标准与关键阈值
- 主要终点钠目标为145-155 mEq/L;亚组分析预设钠目标为150-155 mEq/L。
- 去氨加压素组纳入标准:诊断颅内出血、给予去氨加压素、接受高渗盐水输注。
处置流程与药物剂量
- 原文未提及去氨加压素的具体剂量、给药途径、频次及高渗盐水的输注方案。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:单中心回顾性观察性病历审查;样本量:筛查112例,去氨加压素组25例,匹配高渗盐水单用组25例。
- 主要终点:达到钠目标145-155 mEq/L的比例,去氨加压素组80% vs. 高渗盐水单用组88%,两组相似。
- 次要终点:ICU住院时间、住院时间、钠变化、达标时间、血栓事件、死亡率及复合终点(脑水肿加重、血肿扩大、中线移位、脑疝、需神经外科干预、神经功能恶化)均无差异。
- 亚组分析:高渗盐水单用组48小时内达到钠目标150-155 mEq/L的比例更高(82% vs. 60%,p=0.042)。
证据类型、等级与局限
- 证据类型:单中心回顾性观察性研究;证据等级或推荐强度原文未提及。
- 局限:单中心、回顾性设计、样本量小(每组25例),可能存在混杂偏倚;原文未提及盲法或随机化。
对床旁实践的改变
- 在颅内出血患者中,使用去氨加压素似乎不影响达到钠目标145-155 mEq/L的能力,但若需更高钠目标(150-155 mEq/L),去氨加压素可能降低高渗盐水有效性,应密切监测钠水平。
- 适用人群:颅内出血并接受高渗盐水治疗的患者;不适用人群原文未提及。
- 常见陷阱:不能将本研究结果外推至其他钠目标或不同去氨加压素剂量方案;需注意回顾性研究的局限性。
指南或共识出处
- Neurocritical Care guidelines recommend consideration of desmopressin in antiplatelet-associated intracranial hemorrhage.(原文提及的指南推荐)
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Desmopressin improves hemostasis through the release of factor VIII, von Willebrand factor, and tissue plasminogen activator, and increases platelet adhesion. Neurocritical Care guidelines recommend consideration of desmopressin in antiplatelet-associated intracranial hemorrhage. Studies supporting its use have not evaluated the potential impact of desmopressin on serum sodium levels in patients receiving hypertonic saline therapy. The purpose of this study was to assess the impact of desmopressin on sodium levels and hypertonic saline effectiveness in intracranial hemorrhage.
METHODS: This was a single center retrospective observational chart review. Patients were included in the desmopressin group if they were diagnosed with intracranial hemorrhage, administered desmopressin, and received hypertonic saline infusion. Patients in the hypertonic saline alone group were then matched 1:1 to the patients in the desmopressin group. The primary end point was the effect of desmopressin on reaching a sodium goal of 145-155 mEq/L. The secondary end points included intensive care unit and hospital length of stay, change in sodium, time to reach sodium goal, thrombotic events, mortality, and a composite of increased cerebral edema, hematoma expansion, midline shift, herniation, need for neurosurgical intervention, and neurologic decompensation.
RESULTS: Of 112 patients screened, 25 patients met inclusion criteria for the desmopressin group, and 25 patients were matched with patients in the hypertonic saline alone group. The percentage of patients who reached goal sodium in the desmopressin group compared with hypertonic saline alone was similar (80% vs. 88%, respectively). There were no differences in the secondary end points. In the subgroup analysis, patients in the hypertonic saline group met the predefined sodium goal of 150-155 mEq/L within 48 h more often than those in the desmopressin group (82% vs. 60%, respectively, p = 0.042).
CONCLUSIONS: The use of desmopressin in intracranial hemorrhage does not appear to negatively impact the ability for patients to reach goal sodium of 145-155 mEq/L. However, in patients with higher sodium goals, desmopressin may decrease hypertonic saline effectiveness.
参考来源
- Bowers E, Shaw E, Bromberg W, et al. Desmopressin Administration and Impact on Hypertonic Saline Effectiveness in Intracranial Hemorrhage. Neurocrit Care. 2021. PMID: 34235613. doi:10.1007/s12028-021-01277-2
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。